Updated Jun 17, 9:30 PM · 60 sources analyzed
Key Takeaways
Boehringer Ingelheim terminated its long-term spesolimab HS trial, ceding ground to AbbVie and Novartis in the dermatology market.
AbbVie also terminated Phase 2 NX-13 in ulcerative colitis, increasing pipeline concentration risk around Skyrizi in IBD.
Pfizer's first-line BRAF-mutated colorectal cancer Phase 3 (encorafenib/cetuximab) is approaching data readout with major market-expansion potential.
🏆 Winner
Pfizer — its Phase 3 encorafenib/cetuximab first-line CRC study is nearing a potential data readout that could expand a commercially successful franchise into an earlier, larger patient population.
📉 Loser
AbbVie — terminated both a Phase 2/3 HS extension program (via Boehringer, competitive benefit) and its own NX-13 UC Phase 2, revealing back-to-back pipeline setbacks in inflammatory disease on the same day.
🔭 Watch Next
Results from the completed Cardiol Therapeutics Phase 2 CardiolRx myocarditis trial are awaited; publication of efficacy data would be the first randomized controlled evidence for a drug candidate in acute myocarditis, a field with no approved therapies.
Boehringer Ingelheim terminates spesolimab Phase 2/3 hidradenitis suppurativa study
Boehringer Ingelheim terminated its long-term extension Phase 2/3 trial (NCT06241573) evaluating spesolimab in hidradenitis suppurativa (HS), a painful chronic skin disease, before completion. The termination follows a prior Phase 2b parent study, and no efficacy or safety rationale was disclosed in the registry update. This signals a potential strategic retreat from HS for spesolimab, leaving competitive space for approved agents such as AbbVie's bimekizumab and secukinumab in this high-unmet-need dermatology indication.
ClinicalTrials.gov ↗Boehringer Ingelheim
Spesolimab in Hidradenitis Suppurativa
Specific figures not disclosed. Long-term extension study terminated prior to completion; no efficacy or safety data released in registry update.
Why it matters
The early exit from the HS extension trial suggests Boehringer Ingelheim may have seen insufficient differentiation versus existing IL-17 inhibitors, or encountered enrollment or safety signals not yet disclosed. Watch for any forthcoming data presentation that could clarify whether this was a strategic or scientific decision.
Pfizer
Encorafenib plus Cetuximab (with or without chemotherapy) in Previously Untreated Metastatic Colorectal Cancer (BRAF-mutated)
Specific figures not disclosed. Study active, not yet recruiting new patients; primary endpoint and results not reported in registry update.
Why it matters
With enrollment closed and data maturation underway, a top-line readout could come in the next 12–18 months; a positive result would position Pfizer to challenge standard chemotherapy regimens in the front-line setting. Competitors in BRAF-mutated CRC should prepare for a potential label expansion.
AbbVie
NX-13 in Moderate to Severe Ulcerative Colitis
Specific figures not disclosed. Phase 2 induction study with long-term extension terminated; no efficacy or safety rationale provided in registry update.
Why it matters
AbbVie now faces greater reliance on Skyrizi for UC growth; with multiple competitors advancing next-generation gut-selective agents, the loss of NX-13 may prompt AbbVie to seek external pipeline assets in IBD. Monitor whether the company accelerates BD conversations in this space.
GlaxoSmithKline
GSK Neisseria Gonorrhoeae GMMA Vaccine (NgG) in Gonorrhea (Sexually Transmitted Infection)
Specific figures not disclosed. First-time-in-human proof-of-concept study completed; safety, reactogenicity, efficacy, and immunogenicity evaluated in healthy adults aged 18–50.
Why it matters
If immunogenicity and preliminary efficacy data are favorable at publication, GSK could establish an early lead in the gonorrhea vaccine space ahead of any competitor. Watch for peer-reviewed data release and whether GSK advances to a larger Phase 2 or seeks regulatory guidance on an accelerated path given public health urgency.
Specific figures not disclosed. Long-term extension study terminated prior to completion; no efficacy or safety data released in registry update.
Why it matters
Termination removes spesolimab as a long-term HS contender, consolidating the market around already-approved IL-17 inhibitors and AbbVie's bimekizumab.
Analysis
The early exit from the HS extension trial suggests Boehringer Ingelheim may have seen insufficient differentiation versus existing IL-17 inhibitors, or encountered enrollment or safety signals not yet disclosed. Watch for any forthcoming data presentation that could clarify whether this was a strategic or scientific decision.
Specific figures not disclosed. Phase 2 induction study with long-term extension terminated; no efficacy or safety rationale provided in registry update.
Why it matters
The NX-13 termination narrows AbbVie's UC pipeline beyond Skyrizi, reducing optionality in a crowded inflammatory bowel disease market.
Analysis
AbbVie now faces greater reliance on Skyrizi for UC growth; with multiple competitors advancing next-generation gut-selective agents, the loss of NX-13 may prompt AbbVie to seek external pipeline assets in IBD. Monitor whether the company accelerates BD conversations in this space.
Specific figures not disclosed. Study active, not yet recruiting new patients; primary endpoint and results not reported in registry update.
Why it matters
If successful, a first-line approval in BRAF-mutated metastatic colorectal cancer would expand encorafenib/cetuximab well beyond its current second-line label, significantly enlarging the addressable market.
Analysis
With enrollment closed and data maturation underway, a top-line readout could come in the next 12–18 months; a positive result would position Pfizer to challenge standard chemotherapy regimens in the front-line setting. Competitors in BRAF-mutated CRC should prepare for a potential label expansion.
Specific figures not disclosed. First-time-in-human proof-of-concept study completed; safety, reactogenicity, efficacy, and immunogenicity evaluated in healthy adults aged 18–50.
Why it matters
Completion of the first human efficacy and safety study for a gonorrhea vaccine is a meaningful step given rising antibiotic resistance, with no approved vaccine currently existing for this pathogen.
Analysis
If immunogenicity and preliminary efficacy data are favorable at publication, GSK could establish an early lead in the gonorrhea vaccine space ahead of any competitor. Watch for peer-reviewed data release and whether GSK advances to a larger Phase 2 or seeks regulatory guidance on an accelerated path given public health urgency.
Specific figures not disclosed. Multi-center, double-blind, placebo-controlled trial completed; primary outcome of myocardial recovery (assessed by cardiac MRI) not yet reported in registry.
Why it matters
Acute myocarditis has no approved pharmacotherapy; a positive signal from CardiolRx (a pharmaceutical-grade cannabidiol with anti-inflammatory properties) could open a new treatment category.
Analysis
Cardiol Therapeutics is a small-cap company in a field with no approved drugs, so even a modest efficacy signal could drive significant investor and partnering interest. Watch for a peer-reviewed publication or conference presentation of results, which will be the key value inflection point.
Inhaled Carbon Monoxide Phase 2 Trial Completed in ARDS
A multi-center, randomized, placebo-controlled Phase 2 trial of inhaled carbon monoxide (iCO) for acute respiratory distress syndrome (ARDS) has been completed at Brigham and Women's Hospital, though results have not yet been publicly disclosed in the registry.
Why it matters
ARDS remains an indication with no approved disease-modifying therapies; if iCO demonstrates a clinically meaningful benefit in ventilated patients, it could revive interest in gaseous anti-inflammatory strategies.
Analysis
The completion of this rigorously designed trial sets the stage for a peer-reviewed readout that could influence ARDS drug development strategy industry-wide. Developers active in critical care and acute lung injury should monitor the forthcoming publication for signal strength and effect size before drawing pipeline conclusions.
Moxidectin Dose-Finding Study in Scabies Completed
Medicines Development for Global Health completed a randomized, placebo-controlled Phase 2 dose-finding study of single-dose moxidectin (8 mg, 16 mg, or 32 mg) for scabies in adults, an indication where moxidectin is not currently approved.
Why it matters
Identifying an effective oral dose of moxidectin for scabies could provide a new treatment option for a disease causing significant morbidity globally, particularly in settings where ivermectin resistance is emerging.
Analysis
If a well-tolerated effective dose is confirmed, moxidectin could become a next-generation scabies treatment; companies and global health funders with access to manufacturing or formulation expertise should watch for efficacy results before assessing commercialization or access program viability.
GnRH Antagonist Pre-Treatment Before IVF in Endometriosis: Phase 3 Completed
Yale University completed a Phase 3 randomized trial of oral GnRH (gonadotropin-releasing hormone) antagonist pre-treatment in women with endometriosis undergoing IVF, with live birth rate as the primary endpoint.
Why it matters
A positive live-birth-rate result would support expanded use of oral GnRH antagonists as a pre-IVF optimization strategy, potentially broadening the commercial label for agents such as elagolix or relugolix in the fertility setting.
Analysis
If the live birth rate improvement is clinically meaningful — not just statistically significant — this could reshape IVF protocols for endometriosis patients and open a new indication pathway for marketed GnRH antagonists. Companies holding these assets should track the publication timeline and assess whether a supplemental indication filing is warranted.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
A completed Phase 2 study evaluated BMS-986012 (anti-fucosyl-GM1 antibody) in combination with carboplatin, etoposide, and nivolumab as first-line therapy in extensive-stage small cell lung cancer (NCT04702880). No efficacy or safety results were disclosed in the registry update.
ClinicalTrials.gov ↗Pfizer's Phase 3 study of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer (NCT04607421) is active and not recruiting, suggesting data maturation is underway. Separately, a Phase 1/2 modRNA influenza vaccine study (NCT06436703) was listed as completed.
ClinicalTrials.gov ↗An NCI-sponsored Phase 3 trial testing cemiplimab (REGN2810, Regeneron's PD-1 inhibitor) added to surgery for advanced eyelid and skin squamous cell carcinoma (NCT06568172) is currently suspended. No reason for the suspension was provided in the registry.
ClinicalTrials.gov ↗